Climb Bio (NASDAQ:CLYM) Now Covered by B. Riley Financial

Equities research analysts at B. Riley Financial initiated coverage on shares of Climb Bio (NASDAQ:CLYM) in a note issued to investors on Tuesday. The firm set a “buy” rating and a $26.00 price target on the stock. B. Riley Financial’s price target suggests a potential upside of 297.55% from the stock’s current price.

Several other research firms have also commented on CLYM. Piper Sandler started coverage on Climb Bio in a research report on Friday, February 13th. They set an “overweight” rating on the stock. Truist Financial assumed coverage on Climb Bio in a report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 price objective for the company. Robert W. Baird raised their target price on shares of Climb Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Raymond James Financial initiated coverage on shares of Climb Bio in a report on Tuesday, March 10th. They issued a “strong-buy” rating and a $25.00 target price on the stock. Finally, Wedbush initiated coverage on shares of Climb Bio in a research note on Thursday, March 5th. They set an “outperform” rating and a $12.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.63.

Climb Bio Stock Performance

Shares of CLYM stock opened at $6.54 on Tuesday. The stock’s 50-day moving average is $5.82 and its two-hundred day moving average is $3.70. Climb Bio has a 1 year low of $1.05 and a 1 year high of $8.04. The firm has a market cap of $312.40 million, a price-to-earnings ratio of -7.35 and a beta of -0.25.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.06). As a group, research analysts predict that Climb Bio will post -1.57 EPS for the current year.

Institutional Trading of Climb Bio

Several hedge funds and other institutional investors have recently made changes to their positions in CLYM. Blair William & Co. IL purchased a new stake in shares of Climb Bio during the 4th quarter worth $44,000. Qube Research & Technologies Ltd purchased a new position in shares of Climb Bio in the 2nd quarter valued at about $43,000. Virtu Financial LLC acquired a new stake in shares of Climb Bio in the fourth quarter valued at about $43,000. AQR Capital Management LLC purchased a new stake in Climb Bio during the first quarter worth about $27,000. Finally, Seven Fleet Capital Management LP acquired a new position in Climb Bio during the fourth quarter worth about $306,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.